---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-146179"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:30:09.455852+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO

## Summary
- Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.
- Adrien Sipos, M.D., Ph.D. appointed Interim CMO, effective July 9, 2025; over 25 years I&I experience.
- Dr. Sipos to lead advancement of bempikibart in SIGNAL-AA Phase 2a trial for alopecia areata.
- Topline results from Part B of SIGNAL-AA expected in first half of 2026.
- Prior roles include Biogen, Sanofi Genzyme, Eli Lilly, and President/CMO at PRAXICO.

## SEC filing metadata
- accession: 0001193125-25-146179
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312525146179/0001193125-25-146179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312525146179/d917821d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-146179
- JSON: https://secwatch.observer/filing/0001193125-25-146179.json
- Plain text: https://secwatch.observer/filing/0001193125-25-146179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.